BACKGROUND: The discovery of low-frequency coding variants affecting the risk of coronary artery disease has facilitated the identification of therapeutic targets. METHODS: Through DNA genotyping, we tested 54,003 coding-sequence variants covering 13,715 human genes in up to 72,868 patients with coronary artery disease and 120,770 controls who did not have coronary artery disease. Through DNA sequencing, we studied the effects of loss-of-function mutations in selected genes. RESULTS: We confirmed previously observed significant associations between coronary artery disease and low-frequency missense variants in the genes LPA and PCSK9. We also found significant associations between coronary artery disease and low-frequency missense variants in the genes SVEP1 (p.D2702G; minor-allele frequency, 3.60%; odds ratio for disease, 1.14; P=4.2×10(-10)) and ANGPTL4 (p.E40K; minor-allele frequency, 2.01%; odds ratio, 0.86; P=4.0×10(-8)), which encodes angiopoietin-like 4. Through sequencing of ANGPTL4, we identified 9 carriers of loss-of-function mutations among 6924 patients with myocardial infarction, as compared with 19 carriers among 6834 controls (odds ratio, 0.47; P=0.04); carriers of ANGPTL4 loss-of-function alleles had triglyceride levels that were 35% lower than the levels among persons who did not carry a loss-of-function allele (P=0.003). ANGPTL4 inhibits lipoprotein lipase; we therefore searched for mutations in LPL and identified a loss-of-function variant that was associated with an increased risk of coronary artery disease (p.D36N; minor-allele frequency, 1.9%; odds ratio, 1.13; P=2.0×10(-4)) and a gain-of-function variant that was associated with protection from coronary artery disease (p.S447*; minor-allele frequency, 9.9%; odds ratio, 0.94; P=2.5×10(-7)). CONCLUSIONS: We found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride levels that were lower than those among noncarriers; these mutations were also associated with protection from coronary artery disease. (Funded by the National Institutes of Health and others.).
BACKGROUND: The discovery of low-frequency coding variants affecting the risk of coronary artery disease has facilitated the identification of therapeutic targets. METHODS: Through DNA genotyping, we tested 54,003 coding-sequence variants covering 13,715 human genes in up to 72,868 patients with coronary artery disease and 120,770 controls who did not have coronary artery disease. Through DNA sequencing, we studied the effects of loss-of-function mutations in selected genes. RESULTS: We confirmed previously observed significant associations between coronary artery disease and low-frequency missense variants in the genes LPA and PCSK9. We also found significant associations between coronary artery disease and low-frequency missense variants in the genes SVEP1 (p.D2702G; minor-allele frequency, 3.60%; odds ratio for disease, 1.14; P=4.2×10(-10)) and ANGPTL4 (p.E40K; minor-allele frequency, 2.01%; odds ratio, 0.86; P=4.0×10(-8)), which encodes angiopoietin-like 4. Through sequencing of ANGPTL4, we identified 9 carriers of loss-of-function mutations among 6924 patients with myocardial infarction, as compared with 19 carriers among 6834 controls (odds ratio, 0.47; P=0.04); carriers of ANGPTL4 loss-of-function alleles had triglyceride levels that were 35% lower than the levels among persons who did not carry a loss-of-function allele (P=0.003). ANGPTL4 inhibits lipoprotein lipase; we therefore searched for mutations in LPL and identified a loss-of-function variant that was associated with an increased risk of coronary artery disease (p.D36N; minor-allele frequency, 1.9%; odds ratio, 1.13; P=2.0×10(-4)) and a gain-of-function variant that was associated with protection from coronary artery disease (p.S447*; minor-allele frequency, 9.9%; odds ratio, 0.94; P=2.5×10(-7)). CONCLUSIONS: We found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride levels that were lower than those among noncarriers; these mutations were also associated with protection from coronary artery disease. (Funded by the National Institutes of Health and others.).
Authors: Stefano Romeo; Len A Pennacchio; Yunxin Fu; Eric Boerwinkle; Anne Tybjaerg-Hansen; Helen H Hobbs; Jonathan C Cohen Journal: Nat Genet Date: 2007-02-25 Impact factor: 38.330
Authors: F Mailly; Y Tugrul; P W Reymer; T Bruin; M Seed; B F Groenemeyer; A Asplund-Carlson; D Vallance; A F Winder; G J Miller Journal: Arterioscler Thromb Vasc Biol Date: 1995-04 Impact factor: 8.311
Authors: Urvi Desai; E-Chiang Lee; Kyu Chung; Cuihua Gao; Jason Gay; Billie Key; Gwenn Hansen; Dennis Machajewski; Kenneth A Platt; Arthur T Sands; Matthias Schneider; Isaac Van Sligtenhorst; Adisak Suwanichkul; Peter Vogel; Nat Wilganowski; June Wingert; Brian P Zambrowicz; Greg Landes; David R Powell Journal: Proc Natl Acad Sci U S A Date: 2007-07-03 Impact factor: 11.205
Authors: Wu Yin; Stefano Romeo; Shurong Chang; Nick V Grishin; Helen H Hobbs; Jonathan C Cohen Journal: J Biol Chem Date: 2009-03-07 Impact factor: 5.157
Authors: Mehdi Afshar; Kevin Luk; Ron Do; Line Dufresne; David S Owens; Tamara B Harris; Gina M Peloso; Kathleen F Kerr; Quenna Wong; Albert V Smith; Mathew J Budoff; Jerome I Rotter; L Adrienne Cupples; Stephen S Rich; James C Engert; Vilmundur Gudnason; Christopher J O'Donnell; Wendy S Post; George Thanassoulis Journal: J Am Coll Cardiol Date: 2017-06-20 Impact factor: 24.094
Authors: Jacquelaine Bartlett; Irene M Predazzi; Scott M Williams; William S Bush; Yeunjung Kim; Stephen Havas; Peter P Toth; Sergio Fazio; Michael Miller Journal: Circ Cardiovasc Qual Outcomes Date: 2016-05-10
Authors: Debapriya Basu; Lesley-Ann Huggins; Diego Scerbo; Joseph Obunike; Adam E Mullick; Paul L Rothenberg; Nicholas A Di Prospero; Robert H Eckel; Ira J Goldberg Journal: Arterioscler Thromb Vasc Biol Date: 2018-09 Impact factor: 8.311
Authors: Christi T Salisbury-Ruf; Clinton C Bertram; Aurelia Vergeade; Daniel S Lark; Qiong Shi; Marlene L Heberling; Niki L Fortune; G Donald Okoye; W Gray Jerome; Quinn S Wells; Josh Fessel; Javid Moslehi; Heidi Chen; L Jackson Roberts; Olivier Boutaud; Eric R Gamazon; Sandra S Zinkel Journal: Elife Date: 2018-10-03 Impact factor: 8.140